<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369998">
  <stage>Registered</stage>
  <submitdate>26/01/2016</submitdate>
  <approvaldate>4/02/2016</approvaldate>
  <actrnumber>ACTRN12616000132448</actrnumber>
  <trial_identification>
    <studytitle>A Phase I study of LJPC-401 in healthy adult volunteers</studytitle>
    <scientifictitle>A Phase 1, Placebo-Controlled Study to Determine the Safety, Tolerability and Pharmacokinetics of Escalating Subcutaneous Doses of LJPC-401 in Healthy Adult Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemochromatosis</healthcondition>
    <healthcondition>Thalassemia</healthcondition>
    <healthcondition>Sickle Cell Disease</healthcondition>
    <healthcondition>Myelodysplasia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose of LJPC-401 delivered subcutaneously.  Planned ascending dose cohorts at 5mg, 18mg, 36, and 72mg.  All doses will be administered on-site by study staff.  A Data Monitoring Committee (DMC) comprised of the Principal Investigator (PI), the Sponsors medical representatives, and others as applicable, will meet periodically to review all treatment-emergent adverse events (TEAEs), and to make dose-escalation decisions.</interventions>
    <comparator>Normal saline</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment emergent adverse events, as reported by subjects and/or in response to an open question from study personnel or revealed by observation, physical examination or other diagnostic procedures (i.e., vital signs, clinical laboratory evaluations, ECG).</outcome>
      <timepoint>Day 1: -30- 0 minutes pre-dose, 15-30 minutes, 2 hours, 4 hours, and 8 hours post dose; Day 2, 3, and 8: once daily</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in clinical outcomes: clinical laboratory evaluations including serum iron levels, vital signs, ECGs, physical examinations</outcome>
      <timepoint>Clinical laboratory evaluations once daily at Day -1 or Day 1 (pre-dose/baseline), Day 2, Day 3, Day 8

Total serum iron at Day 1 pre-dose/baseline (-30 to 0 minutes pre-dose), 2 hours, 4 hours, and 8 hours post-dose; once daily at Day 2, Day 3, and Day 8.  Additional serum iron testing at Day 1 pre-dose and Day 8, including ferritin, transferrin, total iron binding capacity (TIBC), and unsaturated iron binding capacity (UIBC).

Vital signs once at Day -1 or Day 1 (pre-dose/baseline); 15-30 minutes, 2 hours, 4 hours, and 8 hours post-dose; once daily at Day 2, Day 3, and Day 8

ECG once at Day -1 or Day 1 (pre-dose/baseline); 4 hours post-dose; once daily at Day 3, and Day 8 (if abnormal at Day 3 only)

Physical examination once at Day -1 or Day 1 (pre-dose/baseline);  2 hours, 4 hours, and 8 hours post-dose; once daily at Day 2, Day 2, and Day 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Immunogenicity testing, assessed by serum assay</outcome>
      <timepoint>Once daily at Day -1 or Day 1 pre-dose/baseline, Day 8, and Day 22.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum iron parameters: total serum iron, ferritin, transferrin, TIBC, and UIBC</outcome>
      <timepoint>Total serum iron at Day 1 pre-dose/baseline (-30 to 0 minutes pre-dose), 2 hours, 4 hours, and 8 hours post-dose; once daily at Day 2, Day 3, and Day 8.  Additional serum iron testing at Day 1 pre-dose and Day 8, including ferritin, TIBC, and UIBC.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics assessed by blood sample: t1/2, Tmax, Cmax, Kel, AUClast, AUC0-8</outcome>
      <timepoint>Day 1 pre-dose/baseline (-30 to 0 minutes pre-dose); 15-30 minutes, 2 hours, 4 hours, and 8 hours post-dose; once daily at Day 2, Day 3, and Day 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Normal, healthy volunteers, negative drug and alcohol tests, BMI 18-32 inclusive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Blood pressure less than 90/60 or greater than 160/100, limited alcohol and tobacco use, infection or other serious underlying medical condition</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>2/02/2016</actualstartdate>
    <anticipatedenddate>31/03/2016</anticipatedenddate>
    <actualenddate>14/03/2016</actualenddate>
    <samplesize>32</samplesize>
    <actualsamplesize>32</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>4/04/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>La Jolla Pharmaceutical Company</primarysponsorname>
    <primarysponsoraddress>10182 Telesis Court, Suite 600
San Diego, CA  92121</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>La Jolla Pharmaceutical Company</fundingname>
      <fundingaddress>10182 Telesis Court, Suite 600
San Diego, CA  92121</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress>None</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase I study of LJPC-401 in healthy adult volunteers.  LJPC-401 is being developed to treat conditions characterized by iron overload, such as hemochromatosis and beta thalassemia.  Bellberry Human Research Ethics Committee approval has been received.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>129 Glen Osmond Rd
Eastwood, SA 3222</ethicaddress>
      <ethicapprovaldate>6/01/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>25/11/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Sam Salman</name>
      <address>Linear Clinical Research
Level 1, B Block, Hospital Avenue
Nedlands, WA 6009</address>
      <phone>+61 (8) 6382 5100</phone>
      <fax />
      <email>SSalman@linear.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Brian Byrnes</name>
      <address>La Jolla Pharmaceutical Company
10182 Telesis Court, Suite 600
San Diego, CA  92121</address>
      <phone>+1-858-207-4264</phone>
      <fax />
      <email>bbyrnes@ljpc.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Brian Byrnes</name>
      <address>La Jolla Pharmaceutical Company
10182 Telesis Court, Suite 600
San Diego, CA  92121</address>
      <phone>+1-858-207-4264</phone>
      <fax />
      <email>bbyrnes@ljpc.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Emily Onkka</name>
      <address>La Jolla Pharmaceutical Company
10182 Telesis Court, Suite 600
San Diego, CA  92121</address>
      <phone>+1-858-257-0951</phone>
      <fax />
      <email>eonkka@ljpc.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>